Search News Archives
Follow us on
Conferences | Events
Lab Bulletin Media Partners
SMi Group

SMi Group

SMi Group

Products

Contact SMi Group


If you have not logged into the website then please enter your details below.

All articles from SMi Group

  SMiā€™s 5th Annual Molecular Diagnostics Conference 2018 agenda released

SMi proudly presents its 5th annual conference on Molecular Diagnostics, taking place at the Holiday Inn Kensington Forum, London, UK on 9th and 10th July 2018, with a half-day post-conference workshops on 11th July 2018....

 

  Key Themes Centred Around Regulation and New Market Dynamics at 8th Annual Biosimilars Industry Summit

Biosimilars 2017 draws from European experience to unveil new market access and commercialisation strategies for an evolving pharmaceutical landscape

Biosimilar drug manufacturers will no longer need to wait an extra six months after FDA approval to launch their product, following a recent U.S Supreme Court decision. The ruling which allows biosimilar drugs to enter the market faster is expected to save patients and the U.S. health system billions of dollars....

 

  FDA EXCLUSIVE: A Spotlight on Regulation in Antibacterial Drug Development

FDA Division of Anti-Infective Products Director, Sumathi Nambair, due to Present at Superbugs & Superdrugs 2017

smiSMi Group are thrilled to have industry expert Sumathi Nambair, provide regulatory and compliance updates on FDA legislation in antibacterial drug development at the 19th annual 2017 Superbugs & Superdrugs show, returning to Central London on 20th and 21st March.

 

  GSK to Present New Evolutions in Targeted RNA Drug Delivery Systems

SMi Group are thrilled to have Jeffrey Ulmer, Head of Preclinical Research & Development from GSK, present a keynote at RNA Therapeutics 2017 when it returns to Central London next February.

Speaker Panel at RNA Therapeutics 2017With a focus on mRNA vaccines, the talk will delve further into key topics surrounding immune responses, animal models, platform technology and rapid response to emerging infectious diseases. In the run-up to his address, Dr Ulmer said: ā€œRNA therapeutics, including recent exciting advancements in RNA-based vaccines, have the potential to be game-changing technologies....

 

  John Rex to Give Exclusive Talk on the Crisis of Antimicrobial Resistance this Fall

Superbugs & Superdrugs USA

Industry expert Dr John Rex will be presenting a special keynote address on the global crisis of antibiotic resistance at SMiā€™s Superbugs & Superdrugs congress this fall.

The industry meeting set to take place on Nov 14th and 15th in Iselin, New Jersey, will gather a global audience of scientific leaders, funding bodies and drug development specialists, providing a focal point to discuss funding opportunities and clinical advancements in drug discovery....

 

  New Agenda for Cancer Vaccines 2016 to Feature Talks from Northwest Biotherapeutics, Genentech, Vaccinogen and MSD

SMi Groups 5th annual Cancer Vaccines conference returns to London this autumn to discuss new breakthroughs in cancer vaccine development.

smiSMi Group is thrilled to present the 5th annual Cancer Vaccines conference, taking place on 21st & 22nd September 2016 in Central London, UK. Aimed at an audience of senior scientists and oncology specialists involved in targeted vaccines and drug research, Cancer Vaccines 2016 will aim to provide a perfect platform to discuss pioneering clinical developments and the next generation of cancer immunotherapy.

 

  BARDA Unveil Plan of Action against Superbugs following $96 Million Funding from US Government

Interview released with US Federal Agency, Biomedical Advanced Research and Development Authority (BARDA), in the run up to SMiā€™s 18th annual show on antimicrobial resistance.

superbugsSMiā€™s 18th annual conference on ā€œSuperbugs & Superdrugsā€ returns to London this March and is thrilled to have Dr. Christopher Houchens, Project Manager of BARDA's Anti-Infective Programme, as one of the keynote speakers for 2016. It was announced last September that the US Government would provide the federal agency, BARDA, which works on national preparedness for chemical and biological threats, funding of $96 million to explore new therapies

 

  12 Crucial Insights into Tackling Antibiotic Resistance at Superbugs 2016

Superbug's and Superdrug's 2016

Have superbugs breached the last line of antibiotic defences for the first time? Industry gathers next March to collaborate on tackling antimicrobial resistance

With a focus on pushing financial and collaborative incentives to accelerate clinical success of antibiotic drugs, the agenda for SMiā€™s 18th annual summit on Superbugs & Superdrugs will spotlight on models for successful partnerships, progressive R&D, strengthening the antibiotic pipeline and pioneering approaches to "smart" antibiotics.

 

  Pre-Filled Syringes-2015: latest updates from Novartis, Janssen, Novo Nordisk, Boehringer Ingelheimā€¦

SMi Group reports: 7th annual Pre-Filled-Syringes Conference will be taking place in London, on the 28-29 January 2015.

smiThe administration of therapeutic drugs via injection is an indispensable delivery method for numerous drugs critical to patient health and well-being. This field is evolving in response to changing patient populations, new classes of powerful therapeutic drugs and healthcare administration initiatives....

 

  Innovation Presentations from Merck, Amgen, Harvest Moon Pharmaceuticals, Lupin ltd at Biosimilars & Biobetters 2014

SMi Group reports: Biosimilars & BiobettersĀ Conference will taking place in London on 29th &Ā 30th September 2014. 3-day event, over 16 innovative presentations, 2 half-day workshops, hours of networking

SMi group logoBuilding unto the success of last year,Ā Biosimilars & Biobetters 2014Ā will allow input from key industry experts in the field to engage in meaningful and important discussions on how to accelerate drug development to market. The agenda aims to bring together pharma, biotech and legal experts explaining the advantages and disadvantages within this growing market, looking atĀ case studies from those who are developing and distributing follow on...

 

  Pre-Filled Syringes Americas: development, manufacture and regulation news for pre-filled syringes and injector devices

Industry Leaders will meet in Iselin, New Jersey, USA to discuss current and emerging trends within the industry

SMi's Pre-Filled Syringes AmericasThe importance of pre-filled syringes and injection devices have never been more pertinent, especially in the US. The challenges of finding a delivery method with patient centric design that avoids leaching, requires swift andĀ decisive decisions early in the development process to avoid unnecessary costs and delays in development. The SMi Group announces its Pre-Filled Syringes America Conference will be taking place in ....

 

  The respected Generics and Patent Strategies event will be returning for the 16th Instalment on 13th & 14th May, London

SMiā€™s event promises to bring together world-renowned experts to present the hottest topics and key challenges faced within the Generics industry today.

Copthorne-Tara-HotelWith presentations and interactive panel discussions, the event will provide attendees with the latest updates on increasing profitability in a highly competitive market, how to overcome some of the IP issues faced when challenging patents andĀ a detailed look at the pricing pressures surrounding an already saturated marketplace...

 

  Are exacerbations the most relevant outcome parameters in COPD clinical trials?

COPD is a life threatening disease which negatively affects normal breathing. It is characterised by persistent blockage of air flow to the lungs. COPD encapsulates chronic bronchitis and emphysema. The most common cause of patients getting COPD is tobacco smoke. This is either from smoking or from second hand smoke

COPDCOPD is not curable and it is under-diagnosed meaning sufferer numbers may be much larger than are recorded currently. COPD cannot be cured, but effective treatment can slow its progress and reduce the numbers of deaths. One of the major focuses of research is attempts to improve patientsā€™ quality of life.

 

  Strategic rationale for clinical development outsourcing among the large pharmaceutical companies MPC

Drugs discovered today can realistically cost upwards of 900 million dollars and around 12 years of development to reach a market.Ā  CRO's have been increasingly used by larger pharma to outsource their clinical research, allowing big pharma to shut down in-house R&D, in practice saving money...

Quote Lab Bulletin and receive Ā£300 discount

 

  Look at ways in which companies can develop pain drugs & treatments at SMiā€™s Pain Therapeutics 2012 Pain Therapeutics 2012
Pain is an incredibly hot topic as it affects all illnesses and all people, in many different ways. This makes it an incredibly lucrative business and one that has not yet been explored in the pharmaceutical industry to its full potential. Pain is also the most common reason patients seek medical care, as it affects the quality of life many people experience and has significant sensory and emotional components. Whilst advances have been made in pain management, few significant ones have occurred, making it harder in recent years to get analgesics to market...

 

  SMi proudly present their 7th annual ADMET conference 7th annual ADMET conference
Don't miss the 7th annual ADMET conference taking place on 9th & 10th July 2012, London, reserve you place today and hear from expert leaders in ADMET as they present in-depth analyses of the very latest In-Vitro, In-Silico developments and DMPK profile optimisation. Get to grips with compounds for Brain and Central Nervous System penetration, computational approaches and predictive models including protein modelling, and attrition in drug discovery and more...

Quote "Lab Bulletin" & save Ā£100

 

  SMi present their 4th annual European Conference on KOL Management & MSL Best Practice in Europe 4th annual European Conference on KOL Management & MSL Best Practice in Europe
SMi are proud to present their 4th annual European Conference on KOL Management & MSL Best Practice in Europe, to be held on 2nd & 3rd July 2012 in Basel, Switzerland. The 2012 event will bring together senior Pharma executives and key opinion leaders to discuss current issues in the field. With presentations from industry representatives from all over the pharmaceutical sector, this event promises to be a unique platform for networking and problem solving...

Quote "Lab Bulletin" & save Ā£100

 

  SMi present their annual RNAi, miRNA & siRNA: A Focus on Nanotechnology & Delivery Conference RNAi and Nanotechnology Conference

SMi present their annual RNAi, miRNA & siRNA: A Focus on Nanotechnology & Delivery Conference to be held on 11th &12th June 2012 in London.. This year's event will focus on the utility of nanotechnology to aid the delivery and development of novel therapeutics in the field of RNAi, miRNA and siRNA and senior industry executives will present attendees with in depth studies on targeted exosomes, structure-activity relationships and antisense technologies...

Quote "Lab Bulletin" to receive Ā£100 discount!!

 

  Clinical Trial Logistics conference returns for its sixth edition Clinical Trial Logistics event
SMi present their 6th annual Clinical Trial Logistics event to be held in London on 22nd & 23rd of May 2012. The event will be focusing on how to improve efficiency and cost effectiveness in your clinical supply chain. Presentations on Shipping validation, transportation studies, timely delivery of clinical trials & understanding and analysis of risk will help you to address any weaknesses in your supply chain, but more importantly, to build on your strengths. In keeping with this, presentations on potential challenges posed by the Olympics and distribution strategy for a virtual company provide unique focus to the discussion...

Quote "Lab Bulletin" to receive Ā£200 discount!

 

  Biomarkers Summit

SMi is excited to announce its much anticipated Biomarkers Summit taking place in London on Monday 31st January and Tuesday 1st February, 2011.Ā  Offering an intensive two day program designed to maximise your time out of the office. The dual track program promises to be the largest and most comprehensive Biomarkers event run by SMi to date. Sponsored by Caprotec, Genstruct & RBM